| 1 |
Jain AK, Blake P, Cordy P, et al. Global trends in rates of peritoneal dialysis [J]. J Am Soc Nephrol, 2012, 23(3): 533-544.
|
| 2 |
Kamijo Y, Iida H, Saito K, et al. Normal peritoneum after nine years of peritoneal dialysis with biocompatible dialysate: a case report [J]. Perit Dial Int,2013,33(6):712-714.
|
| 3 |
Davies SJ, Phillips L, Griffiths AM, et al. What really happens to people on long-term peritoneal dialysis [J]? Kidney Int, 1998, 54(6):2207-2217.
|
| 4 |
Sampimon DE, Coester AM, Struijk DG, et al. The time course of peritoneal transport parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis [ J]. Nephrol Dial Transplant,2011,26(1):291-298.
|
| 5 |
Nakamoto H, Imai H, Kawanishi H, et al. Effect of diabetes on peritoneal function assessed by personal dialysis capacity test in patients undergoing CAPD [J]. Am J Kidney Dis, 2002, 40(5):1045-1054.
|
| 6 |
Mizumasa T, Hirakata H, Kuroki Y, et al. Diabetes influences peritoneal morphology in uremic patients at the initiation of peritoneal dialysis [J]. Perit dial Int,2013,33(2):175-181.
|
| 7 |
Honda K, Hamada C, Nakayama M, et al. Impact of uremia,diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology [J]. Clin J Am Soc Nephrol,2008,3(3):720-728.
|
| 8 |
Stoenoiu MS,De Vriese AS,Brouet A,et al. Experimental diabetes induces functional and structural changes in the peritoneum [J].Kidney Int,2002,62(2):668-678.
|
| 9 |
Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes [J].N Engl J Med,2008,358(24):2560-2572.
|
| 10 |
Wang HY, Lin CY, Chien CC, et al. Impact of uremic environment on peritoneum: a proteomic view [J]. J Proteomics,2012,75(7):2053-2063.
|
| 11 |
Williams JD,Craig KJ,Topley N,et al. Morphologic changes in the peritoneal membrane of patients with renal disease [J]. J Am Soc Nephrol,2002,13(2):470-479.
|
| 12 |
Pletinck A, Consoli C, Van Landschoot M, et al. Salt intake induces epithelial-to-mesenchymal transition of the peritoneal membrane in rats [J]. Nephrol Dial Transplant, 2010, 25(5):1688-1696.
|
| 13 |
Shu KH, Chuang YW, Huang ST, et al. Association of interleukin-1beta gene polymorphism and peritonitis in uremic patients undergoing peritoneal dialysis [J]. Blood purification, 2011, 32(3):156-160.
|
| 14 |
Uchiyama K, Naito K, Tsuchida M, et al. Impact of a genetic polymorphism of the interleukin-1 receptor antagonist on technique survival in peritoneal dialysis patients [J]. Blood purification,2005,23(6):450-458.
|
| 15 |
Flessner MF, Credit K, Henderson K, et al. Peritoneal changes after exposure to sterile solutions by catheter [J]. J Am Soc Nephrol,2007,18(8):2294-2302.
|
| 16 |
Peters T, Potter R, Li X, et al. Mouse model of foreign body reaction that alters the submesothelium and transperitoneal transport[J]. Am J Physiol Renal Physiol,2011,300(1): F283-F289.
|
| 17 |
Chung SH, Heimburger O, Lindholm B. Poor outcomes for fast transporters on PD: the rise and fall of a clinical concern [J].Semin Dial,2008,21(1):7-10.
|
| 18 |
Yang X, Fang W, Bargman JM, et al. High peritoneal permeability is not associated with higher mortality or technique failure in patients on automated peritoneal dialysis [J]. Perit Dial Int,2008,28(1):82-92.
|
| 19 |
Oba I, Shinozaki M, Harada K, et al. Icodextrin-based continuous ambulatory peritoneal dialysis therapy effectively reduces left ventricular mass index and protects cardiac function in patients with end-stage renal disease [J]. Adv Perit Dial,2013,29:14-18.
|
| 20 |
Heaf JG. Peritoneal transport: getting more complicated [J].Nephrol Dial Transplant,2012,27(12):4248-4251.
|
| 21 |
Fernandez-Reyes MJ, Bajo MA, Del PG, et al. The influence of initial peritoneal transport characteristics, inflammation, and high glucose exposure on prognosis for peritoneal membrane function [J].Perit Dial Int,2012,32(6):636-644.
|
| 22 |
McDonald SP, Collins JF, Rumpsfeld M, et al. Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations [J]. Perit Dial Int, 2004, 24(4):340-346.
|
| 23 |
Dejardin A, Robert A, Goffin E. Intraperitoneal pressure in PD patients: relationship to intraperitoneal volume, body size and PDrelated complications [J]. Nephrol Dial Transplant,2007,22(5):1437-1444.
|
| 24 |
Han SH, Lee SC, Ahn SV, et al. Improving outcome of CAPD:twenty-five years' experience in a single Korean center [J]. Perit Dial Int,2007,27(4):432-440.
|
| 25 |
Chow KM, Szeto CC, Cheung KK, et al. Predictive value of dialysate cell counts in peritonitis complicating peritoneal dialysis[J]. Clin J Am Soc Nephrol,2006,1(4):768-773.
|
| 26 |
Ates K, Nergizoglu G, Keven K, et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients [J]. Kidney Inter,2001,60(2):767-776.
|
| 27 |
Wang AY, Woo J, Wang M, et al. Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function [J]. Nephrol Dial Transplant,2005,20(2):396-403.
|
| 28 |
Maiorca R, Brunori G, Zubani R, et al. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study [ J]. Nephrol Dial Transplant,1995,10(12):2295-2305.
|
| 29 |
Bargman JM, Thorpe KE, Churchill DN, et al. Bargman JM,Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study [J]. J Am Soc Nephrol,2001,12(10):2158-2162.
|
| 30 |
Han SH,Lee SC,Ahn SV,et al. Reduced residual renal function is a risk of peritonitis in continuous ambulatory peritoneal dialysis patients [J]. Nephrol Dial Transplant,2007,22(9):2653-2658.
|
| 31 |
Li PK, Chow KM, Wong TY, et al. Effects of an angiotensinconverting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study [J].Ann Intern Med,2003,139(2):105-112.
|
| 32 |
Suzuki H, Kanno Y, Sugahara S, et al. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD [J]. Am J Kidney Dis,2004,43(6):1056-1064.
|
| 33 |
Kolesnyk I, Dekker FW, Noordzij M, et al. Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients [J]. Perit Dial Int,2007,27(4):446-453.
|
| 34 |
Li PK, Cheng YL. Therapeutic options for preservation of residual renal function in patients on peritoneal dialysis [J]. Perit Dial Int,2007,27(Suppl 2): S158-S163.
|
| 35 |
Johnson DW, Clarke M, Wilson V, et al. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function [J]. BMC nephrol,2010,11:25.
|
| 36 |
Johnson DW, Brown FG, Clarke M, et al. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial [J].Nephrol Dial Transplant,2012,27(12):4445-4453.
|
| 37 |
ter WPM, van Ittersum FJ. The new peritoneal dialysis solutions:friends only, or foes in part [J]? Nat Clin Pract Nephrol, 2007, 3(11):604-612.
|
| 38 |
Krediet RT. Cancer antigen 125 as a biomarker in peritoneal dialysis: mesothelial cell health or death [J]? Perit Dial Int,2013,33(6):715-718.
|
| 39 |
Kawanishi K, Honda K, Tsukada M, et al. Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis [J].Perit Dial Int,2013,33(3):242-251.
|
| 40 |
Lee HY, Choi HY, Park HC, et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome [J]. Nephrol Dial Transplant,2006,21(10):2893-2899.
|
| 41 |
Cho Y, Johnson DW, Badve SV, et al. The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients [J]. Kidney Int,2013,84(5):969-979.
|
| 42 |
Nessim SJ, Perl J, Bargman JM. The renin-angiotensin-aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum [J]? Kidney Int,2010,78(1):23-28.
|
| 43 |
Mizuiri S, Ohashi Y, Hemmi H, et al. Effects of new peritoneal dialysis solutions, pyridoxamine and AT1 receptor blocker, on TGFbeta1 and VEGF expression in rat peritoneal mesothelial cells [J].Am J Nephrol,2009,30(3):295-302.
|
| 44 |
Duman S, Gunal AI,Sen S,et al. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution[J]? Perit Dial Int,2001,21(2):219-224.
|
| 45 |
Jing S,Kezhou Y,Hong Z,et al. Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients [J]. Nephrology,2010,15(1):27-32.
|
| 46 |
Wontanatawatot W, Eiam-Ong S, Leelahavanichkul A, et al. An update on RAAS blockade and peritoneal membrane preservation:the ace of art [J]. J Med Assoc Thai,2011,94(Suppl 4): S175-S183.
|
| 47 |
Kolesnyk I, Struijk DG, Dekker FW, et al. Effects of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease [J]. Neth J Med, 2010, 68(1):15-23.
|
| 48 |
Lewis RV, McDevitt DG. Adverse reactions and interactions with βadrenoceptor blocking drugs [J]. Med Toxicol, 1986, 1 (5):343-361.
|
| 49 |
Oules R, Challah S, Brunner FP. Case-control study to determine the cause of sclerosing peritoneal disease [ J]. Nephrol Dial Transplant,1988,3(1):66-69.
|
| 50 |
Hendriks PM, Ho-dac-Pannekeet MM, van Gulik TM, et al.Peritoneal sclerosis in chronic peritoneal dialysis patients: analysis of clinical presentation, risk factors, and peritoneal transport kinetics[J]. Perit Dial Int,1997,17(2):136-143.
|
| 51 |
Stegmayr BG. Beta-blockers may cause ultrafiltration failure in peritoneal dialysis patients [J]. Perit Dial Int,1997,17(6):541-545.
|
| 52 |
Topley N, Petersen MM, Mackenzie R, et al. Human peritoneal mesothelial cell prostaglandin synthesis: induction of cyclooxygenase mRNA by peritoneal macrophage-derived cytokines [J]. Kidney Int,1994,46(3):900-909.
|
| 53 |
Liu H,Peng Y,Liu F, et al. A selective cyclooxygenase-2 inhibitor decreases transforming growth factor-beta1 synthesis and matrix production in human peritoneal mesothelial cells [J]. Cell Biol Int,2007,31(5):508-515.
|
| 54 |
Fabbrini P, Schilte MN, Zareie M, et al. Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysis[J]. Nephrol Dial Transplant,2009,24(12):3669-3676.
|
| 55 |
De Vriese AS, Mortier S, Lameire NH. Non anticoagulant effects of heparin: implications for animal models of peritoneal dialysis [J].Perit Dial Int,2001,21(Suppl 3): S354-S356.
|
| 56 |
Margetts P. Heparin and the peritoneal membrane [J]. Perit Dial Int,2009,29(1):16-19.
|
| 57 |
Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the DiNAS randomized trial [J]. J Am Soc Nephrol,2002,13(6):1615-1625.
|
| 58 |
Pletinck A, Van Landschoot M, Steppan S, et al. Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion [J]. Nephrol Dial Transplant, 2012,27(2):548-556.
|
| 59 |
Li Y, Xie QH,You HZ,et al. Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients-a randomized crossover trial [J]. Perit Dial Int,2012,32(5):507-515.
|
| 60 |
Haslinger B, Goedde MF, Toet KH, et al. Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering[J]. Kidney Int,2002,62(5):1611-1619.
|
| 61 |
Haslinger B, Kleemann R, Toet KH, et al. Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells[J]. Kidney Int,2003,63(6):2065-2074.
|
| 62 |
Duman S, Sen S, Sozmen EY, et al. Atorvastatin improves peritoneal sclerosis induced by hypertonic PD solution in rats [J].Int J Artif Organs,2005,28(2):170-176.
|
| 63 |
Patel S, Mason RM, Suzuki J, et al. Inhibitory effect of statins on renal epithelial-to-mesenchymal transition [J]. Am J Nephrol,2006,26(4):381-387.
|
| 64 |
Aarons CB, Cohen PA, Gower A, et al. Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity [J]. Annals of surgery, 2007, 245(2):176-184.
|
| 65 |
Zhang Y, Kong J, Deb DK, et al. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system [J]. J Am Soc Nephrol,2010,21(6):966-973.
|
| 66 |
Klaus G. Renoprotection with vitamin D: specific for diabetic nephropathy [J]? Kidney Int,2008,73(2):141-143.
|
| 67 |
Coronel F, Cigarran S, Gomis A, et al. Changes in peritoneal membrane permeability and proteinuria in patients on peritoneal dialysis after treatment with paricalcitol-a preliminary study [J].Clin Nephrol,2012,78(2):93-99.
|
| 68 |
Nascimento MM, Suliman ME, Silva M, et al. Effect of oral Nacetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study[J]. Perit Dial Int,2010,30(3):336-342.
|
| 69 |
Feldman L, Shani M, Efrati S, et al. N-acetylcysteine improves residual renal function in peritoneal dialysis patients: a pilot study[J]. Perit Dial Int,2011,31(5):545-550.
|
| 70 |
Katsanos GS, Anogeianaki A, Orso C, et al. Mast cells and chemokines[J]. J Biol Regul Homeost Agents,2008,22(3):145-151.
|
| 71 |
Schilte MN, Celie JW, Wee PM, et al. Factors contributing to peritoneal tissue remodeling in peritoneal dialysis [J]. Perit Dial Int,2009,29(6):605-617.
|
| 72 |
Sajwani SH, Bargman JM. Novel ways to preserve the peritoneal membrane [J]. Adv Perit Dial,2012,28:37-41.
|
| 73 |
Nakayama M, Terawaki H. Multidisciplinary clinical strategies for encapsulating peritoneal sclerosis in peritoneal dialysis: Update from Japan [J]. Int J urol,2014, [Epub ahead of print]
|
| 74 |
Krediet RT, Pannekeet MM, Zemel D, et al. Markers of peritoneal membrane status [J]. Perit Dial Int, 1996, 16 (Suppl 1): S42-S49.
|
| 75 |
Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, et al.Longitudinal follow-up of CA125 in peritoneal effluent [J]. Kidney Int,1997,51(3):888-893.
|
| 76 |
Lee TC, Yang JY, Wang HP, et al. Peritoneal thickening is not inevitable in long-term peritoneal dialysis and is associated with peritoneal transport characteristics: a two-centre sonographic study[J]. Nephrol Dial Transplant,2008,23(3):1005-1010.
|
| 77 |
Hoff CM. Ex vivo and in vivo gene transfer to the peritoneal membrane in a rat model [J]. Nephrol Dial Transplant, 2001, 16(3):666-668.
|
| 78 |
Nie J, Dou X, Hao W, et al. Smad7 gene transfer inhibits peritoneal fibrosis [J]. Kidney Int,2007,72(11):1336-1344.
|